Apoe Epsiolon-4 is Associated With Exacerbation of Cognitive Decline in Patients With Multiple Sclerosis
Background: In previous studies we and others have demonstrated an association with apolipoprotein (APOE) Îµ4 genotype and the presence of cognitive deficits in multiple sclerosis (MS). In this follow-up study, we have assessed whether APOE Îµ4 status exacerbates progression of cognitive deficits in MS. Methods: A total of 197 patients with MS were assessed for APOE genotype, and baseline cognitive performance was measured using a standardized battery of tests. One hundred seventy patients (86.3%) were clinically followed up for 1 year and were assessed for progression of cognitive deficits. Results: The APOE Îµ4 allele was present in 24.7% of patients. During 1-year follow-up, significant progression of cognitive deficits was found in APOE Îµ4 carriers (P=0.001) after logistic regression analysis controlling for sex, ethnicity, age, education, disease duration, severity, and subtype. Conclusions: APOE Îµ4 carriers with MS have worsening progression of cognitive deficits than noncarriers. APOE Îµ4 carrier status predicts cognitive decline in verbal learning and memory.
Medical Subject Headings
Cognitive and Behavioral Neurology
Digital Object Identifier (DOI)
Shi, Jiong; Tu, Jiang Long; Gale, Shawn D.; Baxter, Leslie; Vollmer, Timothy L.; Campagnolo, Denise I.; Tyry, Tuula M.; Zhuang, Yi; and Kuniyoshi, Sandra M., "Apoe Epsiolon-4 is Associated With Exacerbation of Cognitive Decline in Patients With Multiple Sclerosis" (2011). Neurology. 176.